Novel scenarios in targeting HR-positive/HER2-negative breast cancer
Studies provide evidence of potential efficacy for a novel CDK4-selective inhibitor and long-lasting benefits for a pan-AKT inhibitor
Good tolerability of datopotamab deruxtecan supports its place in the treatment of HR+/HER2− breast cancer
In the TROPION-Breast01 trial, adverse events of special interest were generally low grade, easily managed and did not compromise scheduled treatment
Extending the continuum of care for metastatic colorectal cancer
While novel agents continue to enrich the therapeutic armamentarium in this setting, patients ask for a longer survival, but also for a better quality of life
Prolonged use of adjuvant imatinib shows promise in localised GIST
A study reports a disease-free survival benefit with six years of maintenance therapy with imatinib compared to the 3-year standard of care
Fuzuloparib prolongs progression-free survival in HER2 negative metastatic breast cancer
A benefit was observed in women with germline BRCA1/2 mutations when treated with the PARP inhibitor alone or in combination with apatinib
Adjuvant alectinib has been approved by the FDA for resected ALK-positive NSCLC
The tyrosine kinase inhibitor showed to prolong disease-free survival as compared to chemotherapy and clinically meaningful benefit with respect to CNS disease–free survival
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Breast cancer: is the future of PARP inhibitors bright?
Benefits of these targeted agents are not limited to tumours with germline BRCA1/2 mutations, but many questions remain to be answered
Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
Are ADCs in lung cancer living up to expectations?
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC